Ren Chengde, Qiang Ziyang
Department of Urology, Qinghai University Affiliated Hospital Xining 810000, Qinghai, China.
Am J Transl Res. 2023 Dec 15;15(12):6849-6857. eCollection 2023.
To explore the effect of topical estrogen therapy on the expression of estrogen receptor β (ERβ) in bladder tissue of female patients with overactive bladder (OAB).
A total of 58 female OAB patients who were treated in the Affiliated Hospital of Qinghai University were included in this retrospective study. The patients were divided into an estrogen group (28 cases) and a tolterodine group (30 cases). In the estrogen group, patients received topical vaginal estrogen treatment (0.5 mg daily) for 3 consecutive weeks and this was followed by a one-week interval. In the tolterodine group, patients received tolterodine (4 mg once daily) for 3 consecutive weeks and this was followed by a one-week interval. All patients underwent cystoscopy and completed Overactive Bladder questionnaire short form (OAB-q SF). The expression of ERβ in the bladder tissue was detected by immunohistochemistry.
After 12 weeks, there was no statistical difference in the OAB-q scores between the tolterodine and estrogen groups. However, tolterodine treatment significantly improved urinary incontinence than estrogen treatment ( = 0.03). After 12 weeks of estradiol treatment, the expression of ERβ in the bladder tissue was significantly higher than that in the tolterodine group ( < 0.05).
Topical estrogen therapy ameliorates OAB in female patients, and this may be related to improved ERβ expression in the bladder mucosa.
探讨局部雌激素治疗对女性膀胱过度活动症（OAB）患者膀胱组织中雌激素受体β（ERβ）表达的影响。
本回顾性研究纳入了青海大学附属医院收治的58例女性OAB患者。将患者分为雌激素组（28例）和托特罗定组（30例）。雌激素组患者接受局部阴道雌激素治疗（每日0.5 mg），连续3周，随后间隔1周。托特罗定组患者接受托特罗定治疗（每日4 mg），连续3周，随后间隔1周。所有患者均接受膀胱镜检查并完成膀胱过度活动症问卷简表（OAB-q SF）。采用免疫组织化学法检测膀胱组织中ERβ的表达。
1周后，托特罗定组和雌激素组的OAB-q评分无统计学差异。然而，托特罗定治疗改善尿失禁的效果明显优于雌激素治疗（P = 0.03）。雌二醇治疗12周后，膀胱组织中ERβ的表达明显高于托特罗定组（P < 0.05）。
局部雌激素治疗可改善女性患者的OAB，这可能与膀胱黏膜中ERβ表达的改善有关。
